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1. Introduction
The ocular surface is a functional unit mainly formed by the conjunctival and corneal epi‐
thelium (structural  component),  and tear  film (soluble component).  Microorganisms and
environmental  allergens  can  interact  with  the  tear  film,  reach  the  structural  component
and generate an immune response against them. Understanding the cellular and soluble
mediators  that  are  involved  in  these  inflammatory  responses  not  only  helps  in  under‐
standing the mechanisms of  current  treatments,  but  also is  needed to identification and
development of  new therapeutics  targets.  The aim of  this  review was to investigate the
novel  and  developing  therapies,  with  special  emphasis  in  immunomodulatory  drugs/
molecules that could have some clinical indication in the treatment of infectious and aller‐
gic conjunctivitis in few years.
2. Novel therapies in infectious keratoconjunctivitis
2.1. Interferons (IFN) and adenoviral conjunctivitis
Interferons were first described as the major effector cytokines of the host immune response
against viral infections. IFN are well recognized by their potent antiviral properties, howev‐
er IFN production is also induced in response to bacterial ligands of innate immune recep‐
tors and/or bacterial infections, indicating a broader physiological role for these cytokines in
host defence and homeostasis than was originally described.
© 2013 Santacruz et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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Three main types of cytokines compose the IFN family: type I,  type II and type III IFN.
Type I  IFN family is  composed of  16 members,  namely 12 IFNα subtypes,  IFNβ,  IFNε,
IFNκ and IFNω.  By  contrast,  the  type  II  IFN family  includes  only  one  cytokine:  IFNγ,
which also exhibits antiviral activities. The third type of IFN is the IFNλ family, which in‐
cludes IFNλ1 (also known as IL-29), IFNλ2 (also known as IL-28A) and IFNλ3 (also known
as IL-28B). On the basis of protein sequence and structure, type III IFN are markedly differ‐
ent from type I  and type II  IFN and are more similar to members of  the interleukin-10
(IL-10) family; however, they provoke antiviral responses and induce the activation of IFN-
stimulated genes. [1]
Epidemic keratoconjunctivitis (EKC) is a severe ocular infection, caused by highly conta‐
gious adenoviruses Ad8, Ad19, and Ad37. Adenoviral infection of the eye induces keratitis
and conjunctivitis, accompanied by pain, lacrimation, red and swollen eye, as well as de‐
creased vision that may last for months or even years. No specific antiviral drugs are cur‐
rently available for the treatment of EKC or any other infection caused by adenoviruses.
Interestingly, it has been suggested that five strains of different serotypes of adenovirus,
types 3 (AdV3; species B), 4 (species E), 8, 19a and 37 (species D) involved in acute kerato‐
conjunctivitis are highly inhibited by IFN-b and IFN-g in the A549 cell line, [2] However,
IFN therapy in adenoviral keratoconjunctivitis has not been evaluated in clinical trials yet.
2.2. Glycan interactions and EKC
The initial event leading to EKC is binding of the viruses to glycans that contain sialic acid
moieties on epithelial cells in the cornea or conjunctiva through trimeric fiber structures ex‐
tending from the viral particles. The receptor-binding domain is located at the C terminus of
each fiber and contains three separate pockets that each can accommodate one sialic acid
residue. Ad37 was recently shown to bind to cell-surface glycoproteins carrying a glycan
structure named GD1a due to similitude to GD1a ganglioside. The GD1a glycan is a
branched hexasaccharide with a terminal sialic acid residue on each of its two arms. Struc‐
tural studies showed that the two sialic acid moieties dock into two of three sialic acid bind‐
ing sites in the trimeric knob of the Ad37 fiber protein. Most likely, multiple fiber proteins
simultaneously engage several host-cell epitopes containing terminal sialic acids; internali‐
zation and subsequent infection follow. In this context, the molecules named ME0322,
ME0323, and ME0324 were synthetized as a tri- and tetravalent sialic acid compounds, and
interestingly all of theses molecules inhibited the attachment of Ad37 virions to HCE cells in
a dose-dependent manner and were at least two orders of magnitude more effective than
sialic acid, suggesting a promissory inhibitor of Ad37 infection on corneal cells, composed
by a multivalent sialic acid conjugate. If these compounds could be useful as a topical treat‐
ment is not known and needs further investigation. [3]
2.3. Vaccines and Herpetic Stromal Keratitis (HSK)
The disease course in herpetic stromal keratitis (HSK) begins with a primary infection by
herpes simplex virus (HSV) followed by a period during which the virus enters latency in
sensory and autonomic ganglia, after that a reactivation from the trigeminal ganglia follow‐
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ing primary infection induce virus transportation to the ocular mucosa via antero-grade
movement from the ganglia, ultimately causing herpetic keratitis, conjunctivitis and other
ocular sequelae [4]
Many studies have shown that clinical disease is the result of a recruitment of inflammatory
cells, mainly polymorphonuclear cells (PMN), macrophages, and T cells to the corneas of pa‐
tients with HSK. [5] Due to HSK could lead to a potentially blinding disease; several thera‐
peutical strategies are in development to control ocular damage at initial steps of
inflammatory process, i.e. vaccination with different HSV epitopes.
Since the early nineties many attempts have been made to develop a vaccine that would be
effective in preventing HSK. Most of these vaccines were useful to prevent primary HSK
when given prior to HSV infection however failed to prevent recurrent HSK lesions. [6, 7, 8]
Recently, a novel construct with a DNA vaccine expressing herpes simplex virus type 1gD
and IL-21, appears to be effective in protect from primary lesions, and also ameliorates her‐
pes keratitis severity and time course after corneal infection with HSV-1 in the animal model
[9] Nevertheles, future studies are needed in humans HSK to study efficacy of this vaccine.
2.4. Lipids mediators and HSK
Resolvins are lipid mediators that are derived from the v-3 polyunsaturated fatty acids eico‐
sapentaenoic acid and do- cosahexaenoic acid [10] The name of these lipid mediators is re‐
lated to their main function, control of inflammation. Resolvins are involved in prevention
of diapedesis, regulation of dendritic cell costimulatory factors, [11], increased macrophage
phagocytosis of apoptotic neutrophils, inhibition of host tissue inflammatory responses,
with the release of chemokines and cytokines, [12] promotion of tissue repair, and preven‐
tion of host tissue cell death during stress. [13] Interestingly, topical therapy with resolvins
in corneas infected with HSV showed a diminished lesion severity and corneal neovasculari‐
zation when compared with non-treated eyes. Therapy with resolvins, induced a decreased
influx of effector CD4+ T cells and neutrophils to corneal tissue; a diminished production of
proinflammatory cytokines and molecules involved in ocular neovascularization were also
observed during this treatment in the animal model, suggesting resolvins as promissory
molecules in the treatment of HSK.
2.5. Dialyzable Leuckocyte Extracts (DLE) and HSK
DLE were described by Lawrence in 1955, who proved that the extract obtained from a dia‐
lyzed of viable leukocytes from a health donor presenting a positive percutaneous tubercu‐
lin test was able to transfer to a healthy receptor the ability to respond to this test [14] DLE
are constituted by a group of numerous molecules all of them with a molecular weight be‐
tween 1-12 KDa. DLE have been widely used as adjuvant for treating patients with infec‐
tious diseases, and deficient cell-mediated immune response. [15]
The most consistent effects of DLE on the immune system are expression of delayed-type
hypersensitivity (DTH) and production of cytokines. [16] Despite DLE have been extensive‐
ly studied in worldwide, in our country, only Transferon® has been approved for human
Treatments in Infectious and Allergic Conjunctivitis: Is Immunomodulation the Future?
http://dx.doi.org/10.5772/52263
47
use by the federal regulatory authorities of health (COFEPRIS), this clarification is relevant,
since the following immunological activities correspond exclusively to preclinical and clini‐
cal research related to Transferon®. Immunomodulation by Transferon® has been demon‐
strated by restoration of iNOS expression in a mouse model of tuberculosis, provoking
inhibition of bacterial proliferation and significant increase of DTH [17] Transferon® also in‐
duces mRNA expression and IFN-γ secretion in peripheral blood mononuclear cells (PBMC)
in animals with experimental glioma when compared with non-treated animals. [18] Due to
Transferon® induces a Th1 response a clinical study comparing acyclovir treatment and
Transferon® during human herpes virus infection was conducted; in that study patients
treated with Transferon® had low incidence of clinical complications, better pain control,
and also IFN-g was significant increased in serum when compared with patients treated on‐
ly with acyclovir. [19] Then, our group conducted a second clinical trial to evaluate immu‐
nological data and clinical outcome of patients with HSK treated with acyclovir or acyclovir
and Transferon® as adjuvant therapy in patients with herpetic keratitis. Interestingly, pa‐
tients treated with acyclovir and Transferon® showed higher frequency of circulating
CD4+IFN-g+ T cells and lower frequency of circulating CD4+IL4+ T cells after treatment;
[20], when clinical outcome was evaluated, patients who received acyclovir and Transfer‐
on® as adjuvant showed a significant better clinical outcome than patients treated only with
Acyclovir after three months of treatment. (Figure 1)
Despite conclusion of this study was that Transferon® could be used as therapeutical tool as
adjuvant treatment in herpetic keratitis, additional clinical studies with more number of pa‐
tients are needed to confirm these results.
2.6. Amniotic membrane as immunomodulator in infectious keratitis
Amniotic membrane (AM) is the inner layer of the fetal membranes that is in contact with
the fetus. An avascular stroma and single epithelial cells constitute the amniotic membrane
[21] It has been documented in various clinical trials that transplantation of amniotic mem‐
brane is therapeutically useful in different superficial ocular pathologies [22, 23, 24, 25] Its
beneficial effects for transplantation are due to the following characteristics: amniotic mem‐
brane promotes epithelialization, [26] inhibits angiogenesis [27] and has been used as a car‐
rier for ex-vivo expansion of corneal epithelial [28] and endothelial cells [29] Recently, we
demonstrated  that  AM  is  able  to  induce  apoptosis,  inhibit  cell  proliferation  of  human
PBMC,  and abolish  the  synthesis  and the  secretion of  pro-inflammatory  cytokines  even
when they are LPS stimulated in vitro. [30] Similarly to us, Bauer et. al. demonstrated that
amniotic membrane transplantation (AMT) in a mouse model of necrotizing HSK, induced
an increased rate of local macrophages apoptosis, with decrement in proinflammatory cyto‐
kines IL-6, IL-10, IL-12, TNF-α. Nevertheless, in this animal model, the authors suggest that
corneas treated with AMT induced peroxisome proliferator-activated receptor-γ (PPAR- γ)
which is associated to phenotypical change in macrophages, turning them from classically
activated into alternatively activated macrophages or macrophage cell death, through lipid
metabolism and PPAR-γ pathway. [31] In the other hand, animal models of Staphylococcus
aureus keratitis treated with AMT, have suggested that AM improved the healing process,
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resulting in decreased corneal haze and less neovascularization.[32] however the exact mo‐
lecular mechanism remains unknown and needs investigation. Due to a lack in this molecu‐
lar  aspects  clinical  use  of  AM  is  limited  and  only  in  certain  cases  immunomodulation
function of  AM could be exploited,  i.e.  keratitis  with secondary ocular  surface  damage.
(Figure 2)
Figure 1. Representative clinical photographs of patients with herpetic keratitis treated with Acyclovir or treated with
acyclovir and Transferon®. Upper left, Before treatment; Upper right, Same patient, at 3 months of treatment with acy‐
clovir; Low left, Before treatment; Low right, Same patient, at 3 months of treatment with acyclovir and Transferon®
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Figure 2. Clinical photographs of AMT in 67 year old female patient with a history of peripheral infectious keratitis
secondary to trichiasis. Left, AMT covering the lower peripheral corneal defect. Amniotic membrane was folded sever‐
al times over the cornea to increase their anti-inflammatory properties. Right, Same patient, 15 days after AMT, clinical
photograph showing apparent control of hyperaemia and inflammation
2.7. MIF-CD74 blockade in Pseudomona aeurginosa keratitis
Macrophage migration inhibitory factor (MIF) is an integral component of inflammatory re‐
sponses. MIF induces and sustains expression of several pro-inflammatory cytokines.[33]
trough interaction with a receptor complex composed by CD74/CD44 [34] CD74 was first
described as class II invariant chain, while CD44 is an adhesion molecule that binds hyalur‐
onic acid and other matrix metalloproteinases. Interaction of MIF with CD74/CD44 results in
activation of Mitogen-Activated Protein Kinase (MAPK), production of PGE214 and further
induction of inflammatory mediators [35]
Corneal infections by Pseudomonas aeruginosa are more difficult to treat and result in worse
visual outcome than other bacterial corneal ulcers. Unfortunately the existing therapies fail
to control the inflammation secondary to P. aeruginosa keratitis and novel interventions are
needed to alleviate tissue damage resulting from local inflammation, recently two studies
suggest that blockade of MIF-CD74 ligation ameliorate the disease-associated pathology by
decreased proinflammatory mediators and reduced bacterial presence in the cornea [36, 37]
3. Novel therapies in allergic conjunctivitis
Treatment of allergic conjunctivitis can be a challenge by the diverse immunological mecha‐
nisms of damage involved in ocular allergic diseases, reviewed in [38]. To date, a wide range
of antiallergic drops treatments are available and can be confusing due to lack of improve‐
ment at the ocular surface in terms of avoiding anatomical changes in severe cases and con‐
trol of symptoms in the long time period, reviewed in [39, 40, 41]
Hence our primary goal for treating allergic patients should be preferently to recognize al‐
lergy background and ocular inflammation status at the time visit to better establish the
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type and source of antigenic stimuli. In this way, primary action such as avoidance and
clearance of antigen with lubrication is recommended preferently in acute but also in the
late stage of the chronic forms when dry eye could be implicated. Secondary treatment algo‐
rithm includes topical antiallergic agents, which are used towards the reaction characterized
by mast cell activation, release of preformed and newly formed mediators such as hista‐
mine, prostaglandins, leukotrienes, production of chemokines and expression of adhesion
molecules. The aim of treatment in seasonal allergic conjunctivitis and perennial allergic
conjunctivitis is directed to symptom relief and control, whereas the objective in the chronic
forms of vernal keratoconjunctivitis and atopic keratoconjuctivitis will be also to prevent
visual complications or try to identify in early stages possible implication of cornea injury.
Therefore the efficacy of therapeutic agents varies from patient to patient in terms of grade
of severity at the ocular surface, reviewed in [38] and actual local and systemic status activi‐
ty of the immune system making the choice of treatment depending on multiple variables,
each case must be individualized. In general ocular allergic diseases involve mast cell degra‐
nulation that will initiate through inflammatory mediators activation of enzymatic cascades,
giving rise to pro-inflammatory mediators and in consequence antihistamines, mast cell sta‐
bilizers, non-steroidal anti-inflammatory agents, corticosteroids are agents of common use
for acute and chronic conjunctivitis.
Nonetheless this wide range of drugs, management of allergic conjunctivits is still a chal‐
lenge and immune modulation could be the missing link in the therapeutical approach of
ocular allergic diseases.
3.1. Calcineurin inhibitors and atopic keratoconjunctivitis
Calcineurin inhibitors are capable of inducing local immunosuppression more than immu‐
nomodulation. Topical [42] and systemic cyclosporine a (CsA) [43] have been suggested in
the treatment of severe atopic keratoconjunctivitis. Cyclosporine is effective in controlling
ocular allergic inflammation by blocking Th2 lymphocyte proliferation and IL-2 production.
It also reduces eosinophils production via inhibition of IL-5 production. Use of CsA appears
to be safe and the clinical goal for its use is to eliminate the need/dependence of steroids and
favourably alter the long-term prognosis of patients with AKC.
Others calcineurins inhibitors that appears to be well tolerated by patients with severe atop‐
ic blepharoconjunctivitis [44] and severe atopic keratoconjunctivitis [45] and acceptable clin‐
ical outcome are tacrolimus and pimecrolimus, both of them were used first in atopic
dermatitis treatment [46]. To date the real impact of anti-allergic treatment with calcineurin
inhibitors is unknown.
3.2. Mapracorat and eosinophils in ocular allergy
Mapracorat is a novel selective glucocorticoid receptor agonist that maintains a beneficial
anti-inflammatory activity but seems to be less effective in transactivation, resulting in a
lower potential for side effect; it has been proposed for the topical treatment of inflammato‐
ry skin disorders. In vitro, Mapracorat inhibited eosinophil migration and IL-8 release from
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eosinophils or the release of IL-6, IL-8, CCL5/RANTES, and TNF-α from a human mast cell
line with equal potency as dexamethasone, whereas it was clearly less potent than this glu‐
cocorticoid in inducing annexin I and CXCR4 expression on the human eosinophil surface;
in other hand, animal model of allergic conjunctivitis showed that mapracorat was similar to
dexamethasone eye drops in analogous reduction in clinical symptoms of allergic conjuncti‐
vitis and conjunctival eosinophil accumulation. [47] The authors suggest this novel gluco‐
corticoid receptor agonist as a candidate to be used in clinical trials of ocular allergy.
3.3. Omalizumab and allergic diseases
Omalizumab is a biological engineered molecule, targeting the Cε3 domain of the IgE mole‐
cule. It binds with free IgE and prevents free IgE from attaching to high-affinity IgE receptor
(FcεRI) on effector cells such as mast cells, basophils and also on dendritic cells. An IgE-anti-
IgE complex is formed, and as a result, free IgE is decreased. [48] Omalizumab has been well
studied and used in treatment of asthma [49, 50, 51] and other allergic diseases such as uriti‐
caria and and stational rhinitis [52] Like other immunomodulators mentioned above, clinical
trials with allergic conjunctivitis patients are needed to asses the real impact in ocular aller‐
gic diseases.
4. Ocular complications with topical or systemic treatments
Allergic reactions to medication could generate ocular manifestations ranging from mild to
severe and it would not be considered infrequent. Demonstration of allergy to topical medi‐
cations could not be easily evaluated by allergen test, but give some information. Direct
provocation in conjunctiva with suspicious drug has been reported, [53] the authors of this
review do not recommend this method as a diagnostic protocol, however this test could be
used as a research tool to investigate immune responses during allergy to topical medica‐
tion. To evaluate ocular allergy to drug medications, epicutaneous allergen test and immedi‐
ate-reading intradermal tests are carried out to diagnose immediate hypersensitivity
reactions, while atopy patch tests are usually performed to evaluate delayed reactions, re‐
viewed in [38, 54] with this diagnostic methodology, Wijnmaalen et al reported that the
most frequent medication-associated allergies were directed against tobramycin, neomycin
sulphate and thimerosal. [55]
Mild to severe ocular reactions to drug-medications are also associated with systemic medi‐
cations (Figure 3) and in some extreme cases could be life threatening or lead to blinding
disease such Stevens Johnson syndrome. If Systemic reactions to medications are mediated
by IgE hypersensitivity, it could be easy evaluated by flow cytometry with the Basophil Ac‐
tivation Test. (Figure 4)
Principle of this test is simple, basophils are activated in vitro by suspicious medication, if
basophils are sensitized to the drug, basophils became active and up regulate on its surface a
molecule named CD63. [56] CD63 is an intracellular lysosomal protein whose surface ex‐
pression is up regulated also on activated platelets, degranulated neutrophils, monocytes,
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macrophages, and endothelium. To be sure that CD63 expressing cells are basophils, ana‐
lysed cells are also labelled against CD123 and HLA-DR. CD123 is the IL-3Rα, the granulo‐
cytic line, including basophils, express constitutively this cluster of differentiation; [57]
while HLA-DR is expressed on B lymphocytes, monocytes, macrophages, activated T lym‐
phocytes, activated natural killer (NK) lymphocytes, but is absent in Basophils. Altogether
means that by flow cytometry basophils would be CD123+HLA-DR- and only if they were
activated by IgE-allergen or drug-medication basophils would be CD63+ [58] (Figure 4).
 A 
B 
Figure 3. Clinical photograph of a patient with ocular reaction against systemic steroids. Excisional biopsy revealed an
extensive eosinophilic infiltrate remaining angiocentric eosinophilic fibrosis. Demonstration of drug allergy was per‐
formed by flow cytometry.
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Figure 4. Representative cytometer data of Basophil activation test. Analysis gates are shown at upper dot plots. Up‐
per left, a gate was drawn on CD123 positive cells according to SSC characteristics; these cells correspond mainly to
basophils. Upper right, A second gate is performed on HLA-DR negative cells; Dot plots of gated CD123+HLA-DR- cells
(basophils) are displayed. Low left, negative test; Low right, Positive test, markedly up regulated expression of CD63 is
observed.
5. Conclusions
As the prevalence of allergic disease increases around the world, resistance to antibiotics/
antivirals/or antimicotic drugs grows, and virulence of microorganisms improves its capaci‐
ty of infection, it is clear that more effective therapies and disease-modifying agents are
needed. Only treatment evolution will be obtained understanding immune pathophysiologi‐
cal mechanism underlying infectious and allergic diseases. The authors of this review are
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convinced that immunomodulation is part of our future as health professionals and are
working today to make it posible as soon as posible.
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